Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-10-28 | Reverse | 1:12 |
| 2022-07-15 | Reverse | 1:50 |
| 2020-12-31 | Reverse | 1:4 |
| 2019-11-25 | Reverse | 1:25 |
| 2015-05-26 | Reverse | 1000:17609 |
| 2008-12-17 | Reverse | 1:10 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$1.52 ▲ UP 1.67% (+$0.03)About Enveric Biosciences, Inc.
https://www.enveric.com ↗Enveric Biosciences, based in Naples, Florida, develops cannabinoid medicines for cancer care, including treatments for osteoarthritis, cancer-related distress, mental health, and topical skin applications.
INDUSTRY
A PRODUCT ENVERIC BIOSCIENCES, INC. IS KNOWN FOR
Enveric's lead non-hallucinogenic neuroplastogen drug candidate aims to treat depression and anxiety by promoting neuroplasticity safely at home without psychedelic effects.
Enveric Biosciences in 2025
Enveric Biosciences Stock Surges Over 100% Following Positive Patent News for its Neuropsychiatric Treatment Pipeline
In December 2025, Enveric Biosciences' stock experienced a dramatic surge of over 100% in a single day. This significant increase in share price was primarily attributed to the announcement of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to the company's EVM301 series of molecules, which are being developed as non-hallucinogenic treatments for mental health disorders. The positive news was coupled with progress updates on their lead candidate, EB-003, for neuropsychiatric conditions.
Enveric Biosciences Executes Multiple Reverse Stock Splits and Capital Raises in 2025 to Maintain Nasdaq Listing and Fund Clinical Advancement of Lead Drug Candidate
In 2025, Enveric Biosciences' leadership made the critical strategic decision to implement two reverse stock splits, a 1-for-15 in January and a 1-for-12 in October, to regain and maintain compliance with Nasdaq's minimum bid price requirement. Concurrently, the company actively pursued capital infusion through a $5 million public offering and multiple warrant exercises to fund the development of its lead drug candidate, EB-003.
RATINGS SNAPSHOT
Overall rating: C+
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 INDP | $2.33 | COMPARE |
 JSPR | $0.55 | COMPARE |
 ONCO | $0.70 | COMPARE |
 HEPA | $0.12 | COMPARE |
 ZVSA | $0.08 | COMPARE |
 SPRC | $4.35 | COMPARE |
 SLXN | $0.23 | COMPARE |
 SCNI | $1.09 | COMPARE |